Menu

Merck

Merck Launches Biosimilars Clarified, a New Online Educational Resource about Biosimilar Medicines for Patients and the Healthcare Community

, ,

KENILWORTH, N.J. October 14, 2016 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the launch of Biosimilars Clarified (www.merckclarifiesbiosimilars.com), a new educational website for patients, caregivers and the healthcare community that is designed to provide clear, concise and straightforward information about biosimilar medicines. Biosimilars are a type of biological […]

KEYTRUDA® (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients with Previously Treated Metastatic Non-Small Cell Lung Cancer in Data to Be Presented at ESMO 2016 Congress

, , ,

Results from KEYNOTE-010 Include Improved Patient-Reported Health-Related Quality of Life Outcomes and 18-Month Findings of Overall Survival and Progression-Free Survival in Previously Treated Patients Whose Tumors Express PD-L1 (Tumor Proportion Score of One Percent or More) KENILWORTH, N.J. October 9, 2016 –(BUSINESS WIRE)– Merck (NYSE:MRK), known as MSD outside the United States and Canada, today […]

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy

, , , ,

August 8, 2016 KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, at a fixed dose of 200 mg every three weeks, for the treatment of patients with recurrent or […]

Results from Merck’s Phase 3 Study Evaluating ZEPATIER™ (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine

, , , ,

August 8, 2016 KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the publication of results from C-EDGE CO-STAR . C-EDGE CO-STAR is a Phase 3 trial evaluating the use of ZEPATIER™ (elbasvir and grazoprevir) 50mg/100mg tablets in patients with chronic hepatitis C (HCV) genotype (GT) 1, […]

Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Phase III Trial to Evaluate Avelumab as First-line Treatment for Ovarian Cancer

, ,

First Phase III trial evaluating the addition of an immune checkpoint inhibitor to standard of care in first-line ovarian cancer New investigational regimen will evaluate avelumab in extending progression-free survival in treatment-naïve women July 6, 2016 – Merck KGaA, Darmstadt, Germany, and Pfizer (NYSE: PFE) today announced the initiation of a Phase III study, JAVELIN Ovarian […]

Merck and Premier Inc. Collaborate to Prevent Fractures for Osteoporosis Patients

, ,

Companies working alongside providers to develop solutions to serious public health needs KENILWORTH, N.J. and CHARLOTTE, N.C. June 30, 2016 — Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, have agreed to collaborate on the co-development of solutions to help improve population health. […]

Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA® (pembrolizumab) for the Treatment of Multiple Types of Cancer

, , , ,

Collaboration Combines Merck’s Leadership in Immuno-Oncology with Moderna’s Pioneering mRNA Vaccine Technology and Rapid Cycle Time, Small-Batch GMP Manufacturing Capabilities KENILWORTH, N.J. & CAMBRIDGE, Mass. June 29, 2016 — (BUSINESS WIRE) — Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Moderna Therapeutics today announced a strategic collaboration and license agreement to […]

Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA® (pembrolizumab) for the Treatment of Multiple Types of Cancer

, , , ,

Collaboration Combines Merck’s Leadership in Immuno-Oncology with Moderna’s Pioneering mRNA Vaccine Technology and Rapid Cycle Time, Small-Batch GMP Manufacturing Capabilities KENILWORTH, N.J. & CAMBRIDGE, Mass. June 29, 2016 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Moderna Therapeutics today announced a strategic collaboration and license agreement to develop and commercialize […]

Merck Receives 2016 ENERGY STAR Sustained Excellence Award From U.S. Environmental Protection Agency

, ,

Company Receives EPA Honor for 11th Consecutive Year April 1, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it has received an ENERGY STAR 2016 Partner of the Year – Sustained Excellence Award from the U.S. Environmental Protection Agency (EPA) for its continued improvement of […]

Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016

, , , ,

Presentations Include Results from Phase 3 Study Evaluating ZEPATIER™ (elbasvir and grazoprevir) Compared to Sofosbuvir-Containing Regimen, and Results from Studies in Difficult-to-Treat Populations March 30, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the planned presentations of data from the company’s broad chronic hepatitis C […]

«‹ 2 3 4 5›